🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you are in the NY area and looking for updates in #GU, join us in NYC on 4/30 for OncLive.com #Stateofthescience summit. Free for healthcare professionals to register here! shorturl.at/uTCUA

Thank you ASCO daily news for the opportunity to share our (KSridhar) thoughts on NIAGARA: NAC + periop durva for #MIBC - impact on practice and what's ahead. One of the many exciting advances in bladder cancer! Matt Galsky Uromigos Tom Powles dailynews.ascopubs.org/do/niagara-per…

New in NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by Andrea Cercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.10…

🎉 Walk for a cause, earn great rewards, and make an impact! Join the Walk to End Bladder Cancer in one of 19 cities—or walk virtually your way. Raise funds and unlock prizes like t-shirts, tumblers, earbuds & more. Sign up today: secure2.convio.net/bcani/site/SPa…

May 2025 Marks Bladder Cancer Awareness Month - a time to renew our global commitment to raising awareness, breaking barriers, and advancing science. I’m pleased to share our recently published State-of-the-Art Review on Bladder Cancer Diagnosis & Treatment in BMJ (Impact Factor

#bladdercancer systemic #immunotherapy biomarker paper in Journal for ImmunoTherapy of Cancer Society for Immunotherapy of Cancer: Pre-emptive identification of patients at high risk of primary refractory disease on any systemic therapy is challenging but necessary to enable an early switch to other treatment choices before

This #MothersDay, let's remember that while 3 in 4 bladder cancer patients are male, women have worse outcomes at every stage of the disease. Learn why here: bcan.org/women-bladder-…

Just in case anyone missed this? prnewswire.com/news-releases/… UroToday.com Uromigos Bladder Cancer Advocacy Network

Great to meet with Bladder Cancer Advocacy Network to discuss my Bladder Cancer Awareness Bill! As a urologist, I’m incredibly grateful for the network's support of patients across the country facing the challenges of a diagnosis. I look forward to working together to find a cure.

Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 ASCO! 🏢Arie Crown Theater on May 31, 2025 🕐 Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in: ✅ 31% pathologic downstaging ✅ Clear

At #ASCO25 : New Nectin4/PD1 combo data with response rates similar to EVP in bladder cancer. Also DV/toripalimab is better than chemo (press release). There multiple ways of beating 1st line chemo in UC. As chemo becomes less relevant a key question is around ADC sequencing

Our Rochester team was honored to participate in the #BCANWalk to raise awareness for #BladderCancer & support the amazing work of Bladder Cancer Advocacy Network. Wonderful to be part of a national effort to bring all patients an end to bladder cancer. #DrBillTabayoyong Wilmot Cancer Institute UR Medicine

Matt Galsky Icahn School of Medicine at Mount Sinai leads Alliance for Clinical Trials in Oncology A032103 (MODERN) to test the role of DNA released from tumor cells into the blood in guiding the use of #immunotherapy after bladder removal for #bladdercancer treatment: bit.ly/Alliance-A0321… @bladdercancerus

Devastating cut to National Cancer Institute budget - sad to see US cancer research de-prioritized in this time of tremendous potential and innovation #ASCO25

Tour de force discussion of results of CLONEVO IIT by Dr. Bishoy M. Faltas #ASCO25 💊 Abemaciclib with 31% downstaging rate is cis-ineligible MIBC 🧬 CCND1 amp as biomarker of response ⬇️ Ki-67 and pRB, meeting primary endpoint 🔜 Use in conjunction with EV?

SURE-02 trial of SG + pembro in MIBC presented by Andrea Necchi #ASCO25 🔪 Included option for bladder preservation 🔔 44% cCR, 100% metastasis free survival if cCR 🧬 ERBB2 alt associated with response. MTAP loss with non-response

My Case Comp Cancer Ctr colleague Shilpa Gupta presenting analysis of responders from EV-302 #ASCO25 ⬆️ Duration of response to EV/pembro amongst responders 🩻 74% maintain CR at 2 years on EV/P 💊 Median 12-13 cycles EV amongst responders ❓ Can we de-escalate safely in EV/P responders?

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

That’s a wrap here in Buffalo, NY for 2nd Annual Upstate NY Cancer Symposium! Thank you to the local Roswell Park, Wilmot Cancer Institute and the visiting faculty! ✅ Breast Cancer ✅ Lung Cancer ✅ Lymphoma, Myeloma, CLL, & MDS/AML ✅ GI & GU Malignancies #CME #OncTwitter

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. Brian Rini, MD OncoAlert